FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128501601> ?p ?o ?g. }

• W3128501601 endingPage "293" @default.
• W3128501601 startingPage "293" @default.
• W3128501601 abstract "Breast cancer (BC) is the most common cause of cancer-related death in women worldwide. Therapies targeting molecular pathways altered in BC had significantly enhanced treatment options for BC over the last decades, which ultimately improved the lives of millions of women worldwide. Among various molecular pathways accruing substantial interest for the development of targeted therapies are cyclin-dependent kinases (CDKs)—in particular, the two closely related members CDK4 and CDK6. CDK4/6 inhibitors indirectly trigger the dephosphorylation of retinoblastoma tumor suppressor protein by blocking CDK4/6, thereby blocking the cell cycle transition from the G1 to S phase. Although the CDK4/6 inhibitors abemaciclib, palbociclib, and ribociclib gained FDA approval for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative BC as they significantly improved progression-free survival (PFS) in randomized clinical trials, regrettably, some patients showed resistance to these therapies. Though multiple molecular pathways could be mechanistically responsible for CDK4/6 inhibitor therapy resistance, one of the most predominant ones seems to be the fibroblast growth factor receptor (FGFR) pathway. FGFRs are involved in many aspects of cancer formation, such as cell proliferation, differentiation, and growth. Importantly, FGFRs are frequently mutated in BC, and their overexpression and/or hyperactivation correlates with CDK4/6 inhibitor resistance and shortened PFS in BC. Intriguingly, the inhibition of aberrant FGFR activity is capable of reversing the resistance to CDK4/6 inhibitors. This review summarizes the molecular background of FGFR signaling and discusses the role of aberrant FGFR signaling during cancer development in general and during the development of CDK4/6 inhibitor resistance in BC in particular, together with other possible mechanisms for resistance to CDK4/6 inhibitors. Subsequently, future directions on novel therapeutic strategies targeting FGFR signaling to overcome such resistance during BC treatment will be further debated." @default.
• W3128501601 created "2021-02-15" @default.
• W3128501601 creator A5010923347 @default.
• W3128501601 creator A5014990363 @default.
• W3128501601 creator A5017737368 @default.
• W3128501601 creator A5043622673 @default.
• W3128501601 creator A5050622020 @default.
• W3128501601 date "2021-02-01" @default.
• W3128501601 modified "2023-10-01" @default.
• W3128501601 title "Targeting Aberrant FGFR Signaling to Overcome CDK4/6 Inhibitor Resistance in Breast Cancer" @default.
• W3128501601 cites W1499670070 @default.
• W3128501601 cites W1828331863 @default.
• W3128501601 cites W1854073441 @default.
• W3128501601 cites W1894751757 @default.
• W3128501601 cites W1940527094 @default.
• W3128501601 cites W1960850967 @default.
• W3128501601 cites W1965951015 @default.
• W3128501601 cites W1966665452 @default.
• W3128501601 cites W1977681806 @default.
• W3128501601 cites W1981061928 @default.
• W3128501601 cites W1982132411 @default.
• W3128501601 cites W1984245506 @default.
• W3128501601 cites W1988476050 @default.
• W3128501601 cites W1994664175 @default.
• W3128501601 cites W1999175675 @default.
• W3128501601 cites W2001853125 @default.
• W3128501601 cites W2006423274 @default.
• W3128501601 cites W2006864860 @default.
• W3128501601 cites W2008680700 @default.
• W3128501601 cites W2010550709 @default.
• W3128501601 cites W2021703617 @default.
• W3128501601 cites W2024674016 @default.
• W3128501601 cites W2025870139 @default.
• W3128501601 cites W2031915537 @default.
• W3128501601 cites W2033683976 @default.
• W3128501601 cites W2035743945 @default.
• W3128501601 cites W2036418044 @default.
• W3128501601 cites W2039358114 @default.
• W3128501601 cites W2046024621 @default.
• W3128501601 cites W2047408781 @default.
• W3128501601 cites W2053343049 @default.
• W3128501601 cites W2063249586 @default.
• W3128501601 cites W2066059461 @default.
• W3128501601 cites W2070949608 @default.
• W3128501601 cites W2072303535 @default.
• W3128501601 cites W2073260774 @default.
• W3128501601 cites W2073473487 @default.
• W3128501601 cites W2076415360 @default.
• W3128501601 cites W2080722428 @default.
• W3128501601 cites W2086938034 @default.
• W3128501601 cites W2093116780 @default.
• W3128501601 cites W2095509444 @default.
• W3128501601 cites W2098637021 @default.
• W3128501601 cites W2101844536 @default.
• W3128501601 cites W2101904881 @default.
• W3128501601 cites W2102118972 @default.
• W3128501601 cites W2104614171 @default.
• W3128501601 cites W2107977954 @default.
• W3128501601 cites W2113113178 @default.
• W3128501601 cites W2115675418 @default.
• W3128501601 cites W2116215301 @default.
• W3128501601 cites W2118155696 @default.
• W3128501601 cites W2123335871 @default.
• W3128501601 cites W2135504026 @default.
• W3128501601 cites W2144790402 @default.
• W3128501601 cites W2146012023 @default.
• W3128501601 cites W2156038471 @default.
• W3128501601 cites W2161968255 @default.
• W3128501601 cites W2164185692 @default.
• W3128501601 cites W2221464277 @default.
• W3128501601 cites W2229729310 @default.
• W3128501601 cites W2263837770 @default.
• W3128501601 cites W2290950904 @default.
• W3128501601 cites W2295971206 @default.
• W3128501601 cites W2309969893 @default.
• W3128501601 cites W2318816553 @default.
• W3128501601 cites W2338564836 @default.
• W3128501601 cites W2528767298 @default.
• W3128501601 cites W2537675006 @default.
• W3128501601 cites W2552099557 @default.
• W3128501601 cites W2581841075 @default.
• W3128501601 cites W2593997731 @default.
• W3128501601 cites W2620993107 @default.
• W3128501601 cites W2763875663 @default.
• W3128501601 cites W2771397989 @default.
• W3128501601 cites W2805575723 @default.
• W3128501601 cites W2805718747 @default.
• W3128501601 cites W2886814879 @default.
• W3128501601 cites W2889646458 @default.
• W3128501601 cites W2891561885 @default.
• W3128501601 cites W2892043300 @default.
• W3128501601 cites W2903599006 @default.
• W3128501601 cites W2917464640 @default.
• W3128501601 cites W2918928681 @default.
• W3128501601 cites W2925017918 @default.
• W3128501601 cites W2935187964 @default.
• W3128501601 cites W2947428043 @default.
• W3128501601 cites W2947724245 @default.

• next